Company
Headquarters: Moss, Norway
Employees: 47
kr632.3 Million
NOK as of Jan. 1, 2024
US$62.2 Million
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $207.62 B |
Danaher | $171.89 B |
Siemens Healthineers AG | $66.05 B |
DexCom, Inc. | $46.50 B |
IDEXX Laboratories, Inc. | $44.72 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, the United States. It offers in-vitro diagnostic (IVD) for medical laboratories and universities. The company's products include the gentian calprotectin immunoassay used for the measurement of calprotectin in plasma and serum in the diagnosis of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; and Canine CRP, an IVD test for the quantitative determination of Canine CRP in dog serum plasma. It also develops NT-proBNP Immunoassay, a turbidimetric in vitro diagnostic test for the quantitative measurement of N-terminal pro-brain natriuretic peptide. The company was founded in 2001 and is headquartered in Moss, Norway.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Gentian Diagnostics AS has the following listings and related stock indices.
Stock: OSE: GENT wb_incandescent
Stock: FSX: 6FK wb_incandescent